CURRENT EXPANDED ACCESS PROGRAMS
Pfizer Announces CCR5 Antagonist Maraviroc Expanded Access Program
Merck Integrase Inhibitor MK-0518 Expanded Access Program
Tibotec NNRTI TMC125 Expanded Access Program